The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Moxetumomab pasudotox-tdfk approved by FDA for the treatment of HCL

Sep 19, 2018

On 13 September 2018, the US Food and Drug Administration(FDA) announcedthe approval of moxetumomab pasudotox-tdfk (Lumoxiti) intravenous injection for the treatment of adult patients with relapsed or refractory (R/R) hairy cell leukemia (HCL) after two prior lines of systemic therapies, including treatment with a purine nucleoside analog.

Moxetumomab pasudotox-tdfk is a CD22-directed cytotoxin that was granted priority reviewby the FDA on 03 April 2018. The approval follows data from the phase III trial (NCT01829711)in which the overall response rate was 75% (95% CI: 64,84) and durable complete response rate of 30% (95% CI: 20,41).

The FDA noted that common side effects of Moxetumomab pasudotox-tdfk included infusion-related reactions, swelling, nausea, fatigue, headache, fever, constipation, anemia and diarrhea. There is a risk of developing capillary leak syndrome and haemolytic uremic syndrome. Additionally, moxetumomab pasudotox-tdfk is not recommended in patients with severe renal impairment.